The Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: A National Multidisciplinary Stakeholder Project

Journal of Rheumatology

Volumn 34, Issue 11, 2007, Pages 2273-2284

  Maksymowych, Walter P ^a   Gladman, Dafna ^b   Rahman, Proton ^c   Boonen, Annelies ^d   Bykerk, Vivien ^b   Choquette, Denis ^e   Dimond, Sherry ^f   Fortin, Paul ^b   Karsh, Jacob ^g   Klinkhoff, Alice V ^h   Mosher, Dianne ⁱ   Mulholland, Ken ^j   Olszynski, Wojciech P ^k   Russell, Anthony S ^a   Savage, Laurie ^l   Shanner, Laura ^m   Shojania, Kam ^h   Starr, Michael ⁿ   Thomson, Glen ^o   Zummer, Michel ^e   Inman, Robert ^b   more..

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Patient Consumer   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j Patient Consumer   (Canada)

^k UNIVERSITY OF SASKATCHEWAN   (Canada)

^l Spondylitis Association of America   (United States)

^m UNIVERSITY OF ALBERTA   (Canada)

ⁿ MCGILL UNIVERSITY   (Canada)

^o UNIVERSITY OF MANITOBA   (Canada)

more..

Author keywords

Canada; Spondyloarthritis; Treatment recommendations

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR;

ALGORITHM; ANKYLOSING SPONDYLITIS; ARTICLE; CANADA; CONSENSUS; HEALTH PROGRAM; HUMAN; KINESIOTHERAPY; MEDICAL DECISION MAKING; MEDICAL ETHICS; OUTCOME ASSESSMENT; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SPINE SURGERY; SPONDYLITIS; SPONDYLOARTHROPATHY; TOTAL HIP PROSTHESIS; TREATMENT PLANNING;

CANADA; ETHICS, MEDICAL; EVIDENCE-BASED MEDICINE; HUMANS; SOCIETIES, MEDICAL; SPONDYLARTHROPATHIES;

EID: 35948944978     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Maksymowych WP, Inman RD, Gladman D, et al. Canadian Rheumatology Association consensus on the use of anti-tumor necrosis factor-α directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003;30:1356-63.
2. Braun J, Pham T, Sieper J, et al, on behalf of the ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
3. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
4. Pham T, van der Heijde D, Calin A, et al. Initiation of biological agents in ankylosing spondylitis: results of a Delphi study by the ASAS group. Ann Rheum Dis 2003;62:812-6.
5. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
6. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
7. Maksymowych WP. An evaluation of current standards of diagnosis and treatment of ankylosing spondylitis in Canada: Identification of care gaps and educational priorities [abstract]. J Rheumatol 2007;34:1613.
8. The AGREE Collaboration. Appraisal and guidelines for research and evaluation (AGREE) instrument. September 2001. Internet. Available from: www.agreecollaboration.org. Accessed June 27, 2007. 9. Framework on the interaction between the EMEA and patients' and consumers' organizations. London: European Medicines Agency. Internet. Available from: http://www.emea.eu.int/ pdfs/human/pcwp/35451505en.pdf. Accessed June 27, 2007.
9. Summit on standards for arthritis prevention and care. November 1-2, 2005, Ottawa, Canada. Executive report. The Alliance for the Canadian Arthritis Program. Internet. Available from: http://www.arthritis-alliance.ca/docs/ SAPC%20Full%20Report%2020060331%20en.pdf. Accessed June 27, 2007.
10. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
11. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996;39:2004-12.
12. Maksymowych WP. Treatment. In: Weisman MH, Reveille JD, van der Heijde D, editors. Ankylosing spondylitis and the spondyloarthropathies. London: Mosby; 2006:154-86.
13. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1431-4.
14. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1422-30.
15. Garrett S, Jenkinson T, Kennedy G, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;1:2286-91.
16. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
17. Barr SG, Martin L, Chung C, Maksymowych WP. Mandatory pharmacosurveillance - A Canadian model for access to therapy and research. Clin Exp Rheumatol 2004;22 Suppl 35:44-8.
18. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondyloarthropathy. Arthritis Rheum 1995;38:618-27.
19. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
20. Maksymowych WP, Landewe R. Imaging in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006;20:507-19.
21. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
22. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
23. Inman RD, Shojania K, Keystone E, Haraoui B, Leombruno JP, Maksymowych WP. Efficacy of lower dose infliximab in active ankylosing spondylitis - interim results of a Canadian study [abstract]. Arthritis Rheum 2006;54 Suppl:S471.
24. Van den Bosch F, Kruithof E, Baeten D, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
25. Van der Heijde D, Baraf HSB, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis. Arthritis Rheum 2005;52:1205-15.
26. Dougados M, Behier JM, Jolchine I, et al. Efficacy of celecoxib, a cyclo-oxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six week controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug. Arthritis Rheum 2001;44:180-5.
27. Tannenbaum H, Davis P, Russell AS, et al. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Can Med Assoc J 1996;155:77-88.
28. Tannenbaum H, Peloso PMJ, Russell AS, Marlow B. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference. Can J Clin Pharmacol 2000;7 Suppl:4A-16A.
29. Tannenbaum H, Bombardier C, Davis P, Russell AS. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-57.
30. Haibel H, Brandt HC, Song IH, et al. Methotrexate 20 mg SC in ankylosing spondylitis - no efficacy over 4 months treatment in an open label pilot study [abstract]. Arthritis Rheum 2006;54 Suppl: 1820.
31. Lambert RGW, Salonen DC, Rahman P, et al. Adalimumab reduces spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis (AS): 52-week magnetic resonance imaging (MRI) results from the Canadian AS Study [abstract]. Arthritis Rheum 2006;54 Suppl:S799.
32. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 2003;48:3230-6.
33. Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
34. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
35. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
36. Keeling S, Oswald A, Russell AS, Maksymowych WP. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. J Rheumatol 2006;33:558-61.
37. Kobelt G, Andlin-Sobocki P, Maksymowych WP. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006;33:732-40.
38. Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980-4.
39. Maksymowych WP, Dhillon SS, Park R, Salonen D, Inman RD, Lambert RG. Validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) MRI Spinal Inflammation Index: Is it necessary to score the entire spine? Arthritis Rheum 2007;57:501-7.
40. Dougados M, Geuguen A, Nakache JP, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 1999;26:971-4.
41. World Health Organization. International Classification of Functioning, Disability and Health. Geneva: WHO; 2001. Internet. Available from: http://www.who.int/classification/icf. Accessed June 27, 2007.
42. van Echteld I, Cieza A, Boonen A, et al. Identification of the most common problems by patients with ankylosing spondylitis using the International Classification of Functioning, Disability and Health. J Rheumatol 2006;33:2475-83.